Abstract
Pancreatic islet transplantation as a cell-based treatment for diabetes mellitus has been pursued for over quarter of a century, ever since the first successful use of this approach to cure diabetes mellitus in rodents in the 1970s. However, even though autoislet intrahepatic transplantation in patients with chronic pancreatitis who did not have diabetes mellitus was successful in the 1980s, reliable success with alloislet transplantation in patients with diabetes mellitus remained elusive until the year 2000.
The reasons for previous failures appear to include use of corticosteroids as an immunosuppressive agent, a drug that both interferes with islet β-cell function and promotes resistance to insulin action. Corticosteroid-free immunosuppressive regimens in one recent series have permitted much greater success for over 1 year. Benefits accrued in this series include normal fasting glucose levels, normal levels of glycosylated haemoglobin, and total independence from exogenous insulin or other therapy for hyperglycaemia.
These dramatic results have presented the research community with the challenges of replicating these results and, ultimately, with providing solutions to the serious supply and demand issues that will inevitably follow.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery 1972; 72: 175–86
Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230–8
Samols E, editor. The endocrine pancreas. New York: Raven Press Ltd, 1991
Williams P. Notes on diabetes treated with extract and by grafts of sheep’s pancreas. BMJ 1894; 12: 1303–4
Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967; 16: 35–9
Sutherland DE, Matas AJ, Najarian JS. Pancreatic islet cell transplantation. Surg Clin North Am 1978; 58: 365–82
Najarian JS, Sutherland DE, Baumgartner D, et al. Total ornear total pancreatectomy and islet autotransplantation for treatment of chronic pancreatitis. Ann Surg 1980; 192: 526–542
Wahoff DC, Papalois BE, Najarian JS, et al. Autologous islet transplantation to prevent diabetes after pancreatic resection. Ann Surg 1995; 222: 562–75; discussion 575–9
Froberg MK, Leone JP, Jessurun J, et al. Fatal disseminated intravascular coagulation after autologous islet transplantation. Hum Pathol 1997; 28: 1295–8
Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967; 61: 827–37
Gruessner AC, Sutherland DE. Pancreas transplants for United States (US) and non-US cases as reported to the International Pancreas Transplant Registry (IPTR) and to the United Network for Organ Sharing (UNOS). Clin Transpl 1997: 45–59
Theeffect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977–86
Ryan EA, La Rey JRT, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton Protocol. Diabetes 2001; 50: 710–9
Brendel MD, Herring BJ, editors. International Islet Transplant Registry. Vol. 6 no. 1. Giessen, Germany: Justus-Liebig University, 1996
Acknowledgements
This work was supported in part by NIH RO1 DK39994.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Robertson, R.P. Pancreatic Islet Cell Transplantation. Drugs 61, 2017–2020 (2001). https://doi.org/10.2165/00003495-200161140-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200161140-00001